[HTML][HTML] Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a …
J Nishimura, T Satoh, M Fukunaga, H Takemoto… - European Journal of …, 2015 - Elsevier
Introduction The oral neurokinin-1 antagonist aprepitant is recommended in several
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre …
J Nishimura, T Satoh, M Fukunaga… - … Journal of Cancer, 2015 - kyushu-u.elsevierpure.com
Introduction The oral neurokinin-1 antagonist aprepitant is recommended in several
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre …
J Nishimura, T Satoh, M Fukunaga… - … journal of cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Introduction The oral neurokinin-1 antagonist aprepitant is recommended in several
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre …
J Nishimura, T Satoh, M Fukunaga… - European Journal of …, 2015 - ejcancer.com
Introduction The oral neurokinin-1 antagonist aprepitant is recommended in several
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
[引用][C] Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A …
J Nishimura, T Satoh, M Fukunaga… - European Journal of …, 2015 - cir.nii.ac.jp
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer
receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled …
receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled …
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre …
J Nishimura, T Satoh, M Fukunaga, H Takemoto… - European Journal of …, 2015 - infona.pl
The oral neurokinin-1 antagonist aprepitant is recommended in several guidelines for
preventing chemotherapy-induced nausea & vomiting (CINV) due to highly emetogenic …
preventing chemotherapy-induced nausea & vomiting (CINV) due to highly emetogenic …
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre …
J Nishimura, T Satoh, M Fukunaga… - European Journal of …, 2015 - europepmc.org
Methods In this multicentre, open label, randomised, phase 3 trial, we recruited patients with
colorectal cancer who underwent an oxaliplatin-based chemotherapy. Patients were …
colorectal cancer who underwent an oxaliplatin-based chemotherapy. Patients were …
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre …
J Nishimura, T Satoh, M Fukunaga, H Takemoto… - European Journal of …, 2015 - infona.pl
The oral neurokinin-1 antagonist aprepitant is recommended in several guidelines for
preventing chemotherapy-induced nausea & vomiting (CINV) due to highly emetogenic …
preventing chemotherapy-induced nausea & vomiting (CINV) due to highly emetogenic …